Enliven Therapeutics Director Executes Stock Sale Amid Advancements in CML Treatment
Enliven Therapeutics director Richard A. Heyman completed a sale of 1,230 shares of company stock for approximately $32,901 under a pre-arranged trading plan. Concurrently, the company revealed encouraging Phase 1b clinical trial outcomes for its chronic myeloid leukemia drug candidate ELVN-001 and announced significant governance updates including…